Quote:
slcimmuno Member Level Tuesday, 05/23/17 08:42:00 PM
Re: None
Post # of 183095

Good to see CTIX Science getting back some of its shine -- more luster to the lucre (the share price spike).

This Pipeline we have, a pretty tasty P / B / K sandwich ... or: appetizer, main course and dessert ... which is prob whetting the appetites of more than a few Pharma just waiting on more data, more results.

Prurisol... As good as, and maybe better than, Otezla in PsO? Encroaching on the biologics? Maybe applicable to RA and PsA?

Brilacidin... PoC signal in UP/UPS suggesting it might compete with biologics in IBD but w/o the downsides? (Esp w new formulation work, which seems to be underway)... OM a new Standard of Care (prevention) -- Fast Track w/ Breakthrough logically to follow? Possibe extension into other Derm indications (eczema, acne)? Reigniting the ABSSSI Ph 3 under QIDP with potentially a SPA designation?

Kevetrin... one of the few p53 drug candidates in midphase testing, non-genotoxic, with a super-safe profile? Italian group apparently actively researching it? K-Ovarian... Oral formulation being worked on, that would leverage its PK (half-life and clearance)?

Anyway, what a climb in price. + 50% Gotta think some Mako-bitten, AF-hating retail shareholders buying back in along w/ newbies (smart $). Even now we're undervalued - by a factor of at least three IMO ... $3 per share, and maybe a buck or two higher, a fairer valuation with 4 phase 2s underway w game-changing potential.

Hope the buying continues, and it should, as we set up for the summer data reveals. I think the Science is going to continue to deliver the goods -- and whichever Pharma moves on CTIX I think won't be regretting it.